- Home
- NUS vs SRDX Comparison
NUS vs SRDX Comparison
Compare NUS & SRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUS
- SRDX
- Stock Information
- Founded
- NUS 1984
- SRDX 1979
- Country
- NUS United States
- SRDX United States
- Employees
- NUS N/A
- SRDX N/A
- Industry
- NUS Other Pharmaceuticals
- SRDX Medical/Dental Instruments
- Sector
- NUS Health Care
- SRDX Health Care
- Exchange
- NUS Nasdaq
- SRDX Nasdaq
- Market Cap
- NUS 361.7M
- SRDX 416.1M
- IPO Year
- NUS 1996
- SRDX 1998
- Fundamental
- Price
- NUS $8.63
- SRDX $29.02
- Analyst Decision
- NUS Hold
- SRDX Buy
- Analyst Count
- NUS 2
- SRDX 3
- Target Price
- NUS $6.88
- SRDX $43.00
- AVG Volume (30 Days)
- NUS 655.1K
- SRDX 69.2K
- Earning Date
- NUS 05-08-2025
- SRDX 04-30-2025
- Dividend Yield
- NUS 2.78%
- SRDX N/A
- EPS Growth
- NUS N/A
- SRDX N/A
- EPS
- NUS N/A
- SRDX N/A
- Revenue
- NUS $1,679,268,000.00
- SRDX $121,575,000.00
- Revenue This Year
- NUS N/A
- SRDX N/A
- Revenue Next Year
- NUS N/A
- SRDX $3.70
- P/E Ratio
- NUS N/A
- SRDX N/A
- Revenue Growth
- NUS N/A
- SRDX N/A
- 52 Week Low
- NUS $5.32
- SRDX $26.00
- 52 Week High
- NUS $13.90
- SRDX $42.44
- Technical
- Relative Strength Index (RSI)
- NUS 73.05
- SRDX 52.37
- Support Level
- NUS $7.13
- SRDX $28.34
- Resistance Level
- NUS $7.68
- SRDX $29.65
- Average True Range (ATR)
- NUS 0.33
- SRDX 0.79
- MACD
- NUS 0.13
- SRDX 0.16
- Stochastic Oscillator
- NUS 82.70
- SRDX 62.29
About NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
About SRDX Surmodics Inc.
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.